Articles with "keynote 021" as a keyword



Photo by imonnet from unsplash

First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

Sign Up to like & get
recommendations!
Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.9094

Abstract: 9094Background: Data from the randomized, phase 2 cohort G of KEYNOTE-021 (NCT02039674) showed that adding pembro to first-line CP in patients (pts) with advanced nonsquamous NSCLC significantly improved the primary end point of ORR (55%… read more here.

Keywords: pembro; first line; nonsquamous nsclc; cohort ... See more keywords
Photo from wikipedia

24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.9026

Abstract: 9026Background: Cohort G of the phase 1/2 KEYNOTE-021 study (NCT02039674) evaluated pembrolizumab (pembro) + pemetrexed and carboplatin (PC) vs PC in first-line advanced nonsquamous NSCLC. With med... read more here.

Keywords: first line; nonsquamous nsclc; cohort; pemetrexed carboplatin ... See more keywords